Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K. Link, Annette Hay, James R Cerhan, Liting Zhu, Sami Boussetta, Lei Feng, Matthew J. Maurer, Lynn Navale, Jeff Wiezorek, William Y. Go, Christian Gisselbrecht

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractoryDLBCLare limited.SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ¥12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Programof Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.

Original languageEnglish (US)
Pages (from-to)1800-1808
Number of pages9
JournalBlood
Volume130
Issue number16
DOIs
StatePublished - Oct 19 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Refractory materials
Cells
Survival Rate
Salvaging
Non-Hodgkin's Lymphoma
Chemotherapy
Lymphoma
Stem cells
Research
Salvage Therapy
Phase III Clinical Trials
Cytomegalovirus Infections
Stem Cell Transplantation
Neoplasms
Cohort Studies
Therapeutics
Organizations
Recurrence
Drug Therapy

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., ... Gisselbrecht, C. (2017). Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood, 130(16), 1800-1808. https://doi.org/10.1182/blood-2017-03-769620

Outcomes in refractory diffuse large B-cell lymphoma : Results from the international SCHOLAR-1 study. / Crump, Michael; Neelapu, Sattva S.; Farooq, Umar; Van Den Neste, Eric; Kuruvilla, John; Westin, Jason; Link, Brian K.; Hay, Annette; Cerhan, James R; Zhu, Liting; Boussetta, Sami; Feng, Lei; Maurer, Matthew J.; Navale, Lynn; Wiezorek, Jeff; Go, William Y.; Gisselbrecht, Christian.

In: Blood, Vol. 130, No. 16, 19.10.2017, p. 1800-1808.

Research output: Contribution to journalArticle

Crump, M, Neelapu, SS, Farooq, U, Van Den Neste, E, Kuruvilla, J, Westin, J, Link, BK, Hay, A, Cerhan, JR, Zhu, L, Boussetta, S, Feng, L, Maurer, MJ, Navale, L, Wiezorek, J, Go, WY & Gisselbrecht, C 2017, 'Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study', Blood, vol. 130, no. 16, pp. 1800-1808. https://doi.org/10.1182/blood-2017-03-769620
Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017 Oct 19;130(16):1800-1808. https://doi.org/10.1182/blood-2017-03-769620
Crump, Michael ; Neelapu, Sattva S. ; Farooq, Umar ; Van Den Neste, Eric ; Kuruvilla, John ; Westin, Jason ; Link, Brian K. ; Hay, Annette ; Cerhan, James R ; Zhu, Liting ; Boussetta, Sami ; Feng, Lei ; Maurer, Matthew J. ; Navale, Lynn ; Wiezorek, Jeff ; Go, William Y. ; Gisselbrecht, Christian. / Outcomes in refractory diffuse large B-cell lymphoma : Results from the international SCHOLAR-1 study. In: Blood. 2017 ; Vol. 130, No. 16. pp. 1800-1808.
@article{bc7268c932c3473da56a50f58b7f4a14,
title = "Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60{\%} to 70{\%}, up to 50{\%} of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractoryDLBCLare limited.SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ¥12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Programof Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26{\%} (complete response rate, 7{\%}) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.",
author = "Michael Crump and Neelapu, {Sattva S.} and Umar Farooq and {Van Den Neste}, Eric and John Kuruvilla and Jason Westin and Link, {Brian K.} and Annette Hay and Cerhan, {James R} and Liting Zhu and Sami Boussetta and Lei Feng and Maurer, {Matthew J.} and Lynn Navale and Jeff Wiezorek and Go, {William Y.} and Christian Gisselbrecht",
year = "2017",
month = "10",
day = "19",
doi = "10.1182/blood-2017-03-769620",
language = "English (US)",
volume = "130",
pages = "1800--1808",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Outcomes in refractory diffuse large B-cell lymphoma

T2 - Results from the international SCHOLAR-1 study

AU - Crump, Michael

AU - Neelapu, Sattva S.

AU - Farooq, Umar

AU - Van Den Neste, Eric

AU - Kuruvilla, John

AU - Westin, Jason

AU - Link, Brian K.

AU - Hay, Annette

AU - Cerhan, James R

AU - Zhu, Liting

AU - Boussetta, Sami

AU - Feng, Lei

AU - Maurer, Matthew J.

AU - Navale, Lynn

AU - Wiezorek, Jeff

AU - Go, William Y.

AU - Gisselbrecht, Christian

PY - 2017/10/19

Y1 - 2017/10/19

N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractoryDLBCLare limited.SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ¥12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Programof Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.

AB - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting range from 60% to 70%, up to 50% of patients become refractory to or relapse after treatment. Published analyses of large-scale outcome data from patients with refractoryDLBCLare limited.SCHOLAR-1, an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively evaluated outcomes in patients with refractory DLBCL which, for this study, was defined as progressive disease or stable disease as best response at any point during chemotherapy (>4 cycles of first-line or 2 cycles of later-line therapy) or relapsed at ¥12 months from autologous stem cell transplantation. SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization-CORAL and Canadian Cancer Trials Group LY.12) and 2 observational cohorts (MD Anderson Cancer Center and University of Iowa/Mayo Clinic Lymphoma Specialized Programof Research Excellence). Response rates and overall survival were estimated from the time of initiation of salvage therapy for refractory disease. Among 861 patients, 636 were included on the basis of refractory disease inclusion criteria. For patients with refractory DLBCL, the objective response rate was 26% (complete response rate, 7%) to the next line of therapy, and the median overall survival was 6.3 months. Twenty percent of patients were alive at 2 years. Outcomes were consistently poor across patient subgroups and study cohorts. SCHOLAR-1 is the largest patient-level pooled retrospective analysis to characterize response rates and survival for a population of patients with refractory DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=85032021614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032021614&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-03-769620

DO - 10.1182/blood-2017-03-769620

M3 - Article

C2 - 28774879

AN - SCOPUS:85032021614

VL - 130

SP - 1800

EP - 1808

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -